Biotechnology

Midatech Pharma PLC Announces Results for the Year Ended 31 December 2021

April 26, 2022 2:00 AM

ABINGDON, OXFORDSHIRE / ACCESSWIRE / April 26, 2022 / Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces its audited preliminary results for the year ended 31 December 2021. 2021 HIGHLIGHTS Operational · In June 2021, in an R&D update we announced: o Breakthrough data on the successful encapsulation of a biologic using Q-Sphera technology. We...

Read more

Dermata Therapeutics Announces Closing of $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

April 25, 2022 4:50 PM

SAN DIEGO, CA / ACCESSWIRE / April 25, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced the closing of its previously announced private placement with a single institutional investor of 3,773,585 shares of its common stock (or pre-funded warrants to purchase common stock in lieu...

Read more

CORRECTION: Enzolytics, Inc. Reports Progress and Future Plans

April 25, 2022 3:00 PM

This version includes the Safe Harbor statement that was missing from the previous version of this release. COLLEGE STATION, TX / ACCESSWIRE / April 25, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). Enzolytics continues to make significant progress in its multiple therapeutic platforms and outlines here the technical aspects of the implementation of those programs and the Company's plans for the future. Enzolytics Texas...

Read more

Earth Day is Every Day at ITOCO INC.

April 25, 2022 8:15 AM

TORONTO, ON / ACCESSWIRE / April 25, 2022 / ITOCO INC. (OTC Pink:ITMC) ITOCO is pleased to announce its Participation in Earth Day. Although the world came together last week while celebrating International Earth Day, we at ITOCO INC feel the earth should be cared for EVERY DAY! As such, ITOCO is expanding our Nopal cactus cultivation in Portugal - turning arid land into productive cultivation - and we're currently finalizing agreements with a...

Read more

Enzolytics, Inc. Reports Progress and Future Plans

April 25, 2022 7:00 AM

COLLEGE STATION, TX / ACCESSWIRE / April 25, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). Enzolytics continues to make significant progress in its multiple therapeutic platforms and outlines here the technical aspects of the implementation of those programs and the Company's plans for the future. Enzolytics Texas Laboratory Texas A&M University Institute for Preclinical Studies Enzolytics' primary U.S. lab is focused on the...

Read more

Helix Biopharma Corp. Closes Private Placement

April 21, 2022 6:30 PM

RICHMOND HILL, ON / ACCESSWIRE / April 21, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announces that it has closed a private placement financing for net proceeds of $2,002,000 from the issuance of 7,700,000 common shares at a price of $0.26 per common share....

Read more

Lexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs

April 21, 2022 9:05 AM

25th patent grant is Lexaria's first-ever patent for the enhanced delivery of antivirals KELOWNA, BC / ACCESSWIRE / April 21, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the Company is receiving its first-ever patent for the use of DehydraTECH technology in the enhanced delivery of antiviral drugs. Lexaria has received notification from the...

Read more

Dermata Therapeutics Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

April 21, 2022 9:00 AM

SAN DIEGO, CA / ACCESSWIRE / April 21, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) and (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $5.0 million of its common stock (or pre-funded warrants to purchase...

Read more

Aqualung Therapeutics Extends Global Reach With LeaderMed License Agreement

April 20, 2022 5:00 PM

TUCSON, AZ / ACCESSWIRE / April 20, 2022 / Aqualung Therapeutics, an early stage immunotherapeutics biotech company developing an anti-inflammatory therapeutic platform for serious unchecked inflammatory disorders, announced the signing of a license agreement with the LeaderMed Health Group Limited ("LeaderMed"). The License Agreement provides LeaderMed with Asia-Pacific regional rights to further develop, manufacture, and commercialize the...

Read more

Lexaria Commences Multi-Week Human Clinical Hypertension Study

April 19, 2022 9:05 AM

HYPER-H21-4 will evaluate DehydraTECHTM-CBD for reducing blood pressure together with other potential clinical benefits This study is designed to enhance Lexaria's probabilities of success with its expected subsequent Investigational New Drug application filing KELOWNA, BC / ACCESSWIRE / April 19, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased...

Read more

Helix Biopharma Corp. Announces Appointment of Permanent CEO and Independent Board Members

April 18, 2022 11:00 AM

RICHMOND HILL, ON / ACCESSWIRE / April 18, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platformDOS47, is pleased to announce that Artur Gabor has been appointed as the Company's Chief Executive Officer with immediate effect. The Company is also pleased to announce the addition of...

Read more

Lexaria's Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results

April 14, 2022 8:45 AM

Data From This Human Study, Together With the Findings From Lexaria's Other Previously Announced Successful Studies, Intended To Support the Company's Plans To Seek Approvals by the U.S. Food and Drug Administration KELOWNA, BC / ACCESSWIRE / April 14, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that all data analyses from its simulated...

Read more

Helix Biopharma Corp. Announces Extension of Early Warrant Exercise Incentive Program and Receipt of Private Placement Subscription

April 13, 2022 5:00 PM

RICHMOND, ON / ACCESSWIRE / April 13, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, is pleased to announce that it has received conditional approval from the Toronto Stock Exchange (the "TSX") to extend its previously announced Early Warrant Exercise Incentive Program...

Read more

Apollo Endosurgery to Report First Quarter Results on May 3, 2022

April 13, 2022 8:45 AM

AUSTIN, TX / ACCESSWIRE / April 13, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (Nasdaq:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the first quarter ended March 31, 2022 on Tuesday, May 3, 2022, after market close. In conjunction with the release, Apollo will host a live...

Read more

Oncology Pharma Completes Feasibility Phase of its Licensed Nanoemulsion Drug Delivery System to Treat Cancer

April 13, 2022 7:30 AM

SAN FRANCISCO, CA / ACCESSWIRE / April 13, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma ("The Company") is pleased to announce that it has completed the initial feasibility phase of its licensed dactinomycin nanoemulsion. The successful completion of the feasibility stage marks the initial planned milestone for this development project. Data is currently under evaluation and discussions regarding future development and milestones...

Read more

Silver Phoenix Announces Reverse Takeover by Atlas Biotechnologies, Cambrosia and AgMedica Bioscience

April 12, 2022 12:00 PM

VANCOUVER, BC / ACCESSWIRE / April 12, 2022 / Silver Phoenix Resources Inc. (CSE:SP) ("SPR" or the "Company") is pleased to announce that it has entered into a binding memorandum of understanding dated as of April 8, 2022 (the "MOU") with Atlas Biotechnologies Inc. ("Atlas"), AgMedica Bioscience Inc. ("AgMedica") and Cambrosia Ltd. ("Cambrosia") (collectively, the "Target"). The MOU outlines the proposed terms and conditions pursuant to which...

Read more

Qrons Announces Filing Of Provisional Patent Application In Furtherance Of Its QS200 Product Candidate

April 12, 2022 9:30 AM

NEW YORK, NY / ACCESSWIRE / April 12, 2022 / Qrons Inc. (OTCQB:QRON), an innovative biotechnology company dedicated to developing next generation treatments for unmet neuronal diseases, using tissue engineering, stem cells and machine learning synergic technologies announced the filing on April 3, 2022, of a United States Provisional Patent Application for inventions of Therapeutic Polypseudorotaxane Hydrogels, thereby providing Qrons with the...

Read more

Lexaria Provides Update on Human Nicotine Study NIC-H22-1

April 12, 2022 9:10 AM

Lexaria's DehydraTECH-nicotine pouch performance will be compared to existing leading brands currently sold in the United States such as ON! and Zyn KELOWNA, BC / ACCESSWIRE / April 12, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces details of human nicotine study NIC-H22-1, which is expected to begin dosing this summer. Study NIC-H22-1 is a...

Read more

EV Biologics Isolates Primary Cells for Nanoparticle Production & Accelerated Cell Line Development

April 12, 2022 9:00 AM

TAMPA, FL / ACCESSWIRE / April 12, 2022 / EV Biologics Corp, OTC PINK:YECO, today announced that it has succeeded in isolating primary progenitor cells from tissue using a xeno-free process. The Company has been developing an improved process for isolation of progenitor cells from tissue to generate cell banks for therapeutic nanoparticle production and further cell line development. This Process Development will continue with iterative...

Read more

Nascent Biotech and BioTools Partner in the Fight Against Cancer Using ROA to Define the Higher Order Structure of PTB, a Unique Monoclonal Antibody

April 12, 2022 8:00 AM

VERO BEACH, FL / ACCESSWIRE / April 12, 2022 / Nascent Biotech, developer of Pritumumab (PTB), a monoclonal antibody showing promise in the treatment of brain cancer, has partnered with BioTools, Inc to clearly define PTB's higher order molecular structure (HOS). Nascent is exploring the potential of modifying the antibody to enhance its effectiveness and to broaden its therapeutic application. BioTool's groundbreaking ROA laser-based technology...

Read more